Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term safety and tolerability of subcutaneous TEV-48125 (fremanezumab) for preventive treatment of migraine
jRCT2080223670Phase 3Completed
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Start
- Oct 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
01
Overview
Phase 3, randomised, open-label trial of fremanezumab in chronic migraine and episodic migraine (2 arms), sponsored by Otsuka Pharmaceutical Co., Ltd. Primary endpoint: Long-term safety and tolerability of fremanezumab. Started Oct 2017; status: completed.
02
Drugs
fremanezumab
03
Conditions
chronic migraineepisodic migraine
Beyond the preview
Go deeper on jRCT2080223670.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223670.